Verastem, Inc.
VSTM Healthcare Biotechnology
Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1,775.4%, EPS grew 10.3%, free cash flow fell 34.4% and total debt was flat, each against the same quarter a year earlier.
Follow VSTM
Verastem, Inc. (VSTM) EV/Sales
As of 16 October 2026, Verastem, Inc. (VSTM) trades at a EV/Sales of 9.3×. Over the past ten years it has ranged from −5.3× (October 2022) to 235× (November 2021); the current reading is higher than 72% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.2× | (8.67%) |
| FY2024 | 11.1× | 113.18% |
| FY2022 | 5.2× | (95.85%) |
| FY2021 | 126× | 5,335.03% |
| FY2020 | 2.3× | (68.55%) |
| FY2019 | 7.4× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | (55.76%) |
| Mar 2026 | 8.5× | (16.30%) |
| Dec 2025 | 10.2× | (55.68%) |
| Sep 2025 | 23.0× | 80.49% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| ARDX Ardelyx, Inc. compare | 1.7× |
| KURA Kura Oncology, Inc. compare | 3.9× |
| VSTM Verastem, Inc. | 9.3× |
| GLUE Monte Rosa Therapeutics, Inc. compare | 12.8× |
| ALMS Alumis Inc. compare | 37.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)